# US 2021/0341409 A1 · Non-invasive bladder cancer detection system via liquid and gaseous phase analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341409 A1
- Document ID: US20210341409A1
- Status: Published application
- Kind: A1
- Application number: 17/242,750
- Filed: 2021-04-28
- Published: 2021-11-04
- Earliest claimed: 2020-05-01
- Assignees: Regents of the University of Minnesota
- Applicants: Boston Scientific Scimed, Inc.
- Inventors: Christopher Brian Rognrud; Vijay Koya; August Judisch; Anthony Frank Tassoni, JR.; Gregory J. Sherwood; Kate Louise Frost; Justin Theodore Nelson
- Web page: https://patentgrep.com/patent/US20210341409A1

## CPC

- G01N 27/227: {Sensors changing capacitance upon adsorption or absorption of fluid components, e.g. electrolyte-insulator-semiconductor sensors, MOS capacitors (G01N27/225 takes precedence)}
- B01L 3/508: {Rigid containers without fluid transport within}
- G01N 33/493: urine
- G01N 33/54373: {involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 70/60: relating to pathologies
- B01L 2200/06: Fluid handling related problems
- B01L 2300/0663: Whole sensors
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Embodiments herein relate to non-invasive bladder cancer detection systems and methods. In an embodiment, a method for detecting a disease state in a subject is included. The method includes obtaining a liquid biological sample from the subject and placing it into a container and contacting the liquid biological sample with a first chemical sensor element, where the first chemical sensor element can include a plurality of discrete graphene varactors. The method can include sensing and storing capacitance of each of the discrete graphene varactors to obtain a first sample data set. Other embodiments are also included herein.

## Claims

### Claim 1

A method for detecting a disease state in a subject, comprising:
obtaining a liquid biological sample from the subject and placing it into a container;
contacting the liquid biological sample with a first chemical sensor element, the first chemical sensor element comprising a plurality of discrete graphene varactors; and
sensing and storing capacitance of each of the discrete graphene varactors to obtain a first sample data set.

### Claim 2 (depends on 1)

The method of claim 1, wherein obtaining a liquid biological sample comprises obtaining one or more of a urine sample, a blood sample, a liquid suspension comprising an organ biopsy sample, a sputum sample, a sweat sample, or a cell culture sample.

### Claim 3 (depends on 1)

The method of claim 1, further comprising classifying the first sample data set into one or more preestablished disease states.

### Claim 4 (depends on 1)

The method of claim 1, further comprising contacting a gas from a headspace surrounding the liquid biological sample with a second chemical sensor element comprising a plurality of discrete graphene varactors.

### Claim 5 (depends on 4)

The method of claim 4, wherein the headspace surrounding the liquid biological sample includes a volume of a gas.

### Claim 6 (depends on 4)

The method of claim 4, further comprising bubbling the liquid biological sample with a gas prior to contacting the gas from the headspace with a second chemical sensor element.

### Claim 7 (depends on 1)

The method of claim 1, wherein the container is flushed with an inert gas prior to placing the liquid biological sample into the container.

### Claim 8 (depends on 1)

The method of claim 1, wherein the liquid biological sample is contacted with the first chemical sensor element by submersing the first chemical sensor element into the liquid biological sample for a predetermined amount of time.

### Claim 9 (depends on 1)

The method of claim 1, wherein the liquid biological sample is contacted with the first chemical sensor element by capillary action of a fluid across the first chemical sensor element.

### Claim 10 (depends on 1)

The method of claim 1, wherein the liquid biological sample is incubated in the container for a period of time before the liquid biological sample is contacted with a chemical sensor element.

### Claim 11 (depends on 1)

The method of claim 1, wherein sensing and storing capacitance of the discrete graphene varactors to obtain a sample data set is performed across a range of bias voltages, wherein the range of bias voltages is from −3 V to 3 V.

### Claim 12

A method for detecting a disease state in a subject, comprising:
obtaining a liquid biological sample from the subject and placing it into a container having a headspace above the liquid biological sample;
contacting the liquid biological sample with a first chemical sensor element, the first chemical sensor element comprising a plurality of discrete graphene varactors;
contacting a gas from the headspace above the liquid biological sample with a second chemical sensor element comprising a plurality of discrete graphene varactors; and
sensing and storing capacitance of each of the discrete graphene varactors of each of the first chemical sensor element to obtain a first sample data set and the second chemical sensor element to obtain a second sample data set.

### Claim 13 (depends on 12)

The method of claim 12, further comprising classifying each of the first sample data set and the second sample data set into one or more preestablished disease states.

### Claim 14 (depends on 12)

The method of claim 12, wherein obtaining a liquid biological sample comprises obtaining one or more of a urine sample, a blood sample, a liquid suspension comprising an organ biopsy sample, a sputum sample, a sweat sample, or a cell culture sample.

### Claim 15 (depends on 12)

The method of claim 12, further storing additional subject-specific data regarding the subject beyond sensed capacitance, the additional subject-specific data comprising at least one of:
prior disease states of the subject;
age of the subject;
results of a physical examination;
symptoms experienced by the subject;
current treatments received by the subject;
prior treatments received by the subject; and
prior data regarding specific biomarkers of one or more disease states.

### Claim 16

A system for detecting a disease state comprising:
a container, the container comprising a housing adapted to contain a liquid biological sample of a subject, the housing defining a headspace comprising a volume of a gas;
a first chemical sensor element configured to be contacted with the liquid biological sample, the first chemical sensor element comprising a plurality of discrete graphene varactors; and
a sensing device configured to interface with the first chemical sensor element, the sensing device further configured to sense a capacitance of the plurality of discrete graphene varactors.

### Claim 17 (depends on 16)

The system of claim 16, further comprising a second chemical sensor element in fluid communication with the headspace, the second chemical sensor element comprising a plurality of discrete graphene varactors.

### Claim 18 (depends on 16)

The system of claim 16, the plurality of discrete graphene varactors each comprising one or more surface modifications of a graphene surface.

### Claim 19 (depends on 18)

The system of claim 18, wherein the surface modifications of the plurality of discrete graphene varactors are configured to detect one or more biomarkers of a disease state, the biomarkers comprising DNA, RNA, nucleolin, tumor cells, cell surface receptor proteins, C-reactive protein, transcription factors, cytokines, volatile organic compounds, exosomes, or derivatives and fragments thereof.

### Claim 20 (depends on 16)

The system of claim 16, wherein the plurality of discrete graphene varactors are configured in an array.
